Comparative Pharmacology
Head-to-head clinical analysis: MEXATE versus PADCEV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEXATE versus PADCEV.
MEXATE vs PADCEV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MEXATE is an antimetabolite that inhibits dihydrofolate reductase (DHFR), reducing tetrahydrofolate synthesis and interfering with DNA, RNA, and protein synthesis. It also inhibits thymidylate synthetase and has immunomodulatory and anti-inflammatory effects.
Enfortumab vedotin is an antibody-drug conjugate (ADC) directed against Nectin-4, a cell adhesion molecule expressed on urothelial carcinoma cells. The antibody portion binds to Nectin-4, leading to internalization and release of the microtubule-disrupting agent monomethyl auristatin E (MMAE) via proteolytic cleavage. MMAE binds to tubulin and inhibits microtubule polymerization, inducing G2/M phase arrest and apoptosis.
10-25 mg/m2 orally or intramuscularly once weekly for rheumatoid arthritis; 50 mg/m2 intravenously once weekly for psoriasis; 30-40 mg/m2 intravenously weekly for certain cancers (dose varies by protocol).
1.25 mg/kg (up to 125 mg) intravenously on days 1, 8, and 15 of a 28-day cycle
None Documented
None Documented
Terminal elimination half-life is 3-10 hours for low-dose therapy (≤30 mg/m²). For high-dose therapy (>100 mg/m²), terminal half-life extends to 8-15 hours due to saturable elimination. A third, prolonged terminal phase (8-72 hours) is observed in some patients due to enterohepatic recirculation.
Approximately 3.4 days (range 2.8-4.2 days) at steady state, supporting every-3-week dosing. Terminal half-life consistent with IgG1 clearance.
Renal excretion of unchanged drug is the primary route of elimination, accounting for 80-90% of the dose. Biliary/fecal excretion is minor (<10%).
Primarily metabolized via catabolism into small peptides and amino acids; minimal renal excretion (<5% unchanged drug in urine). No biliary/fecal data available.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent